文献速递消化内镜消化道肿瘤与早癌

具有进展期组织学特征的小息肉不增加异时性进展期结直肠肿瘤风险

Diminutive Polyps With Advanced Histologic Features Do Not Increase Risk for Metachronous Advanced Colon Neoplasia.
PubMed 文献 · Gastroenterology · 2018-11-02

结果显示,因小息肉进展期特征归为高风险的患者比例在粪便免疫化学检测队列为0.8%、结肠镜队列为0.4%(P=0.25),其异时性进展期肿瘤风险与低风险患者无显著差异(17.6% vs 14.6%,RR 1.13,95%CI 0.79-1.61)。结论认为小息肉伴进展期组织学特征不增加异时性进展期肿瘤风险。

要点

  • 在51510枚小息肉中,进展期组织学特征在FIT队列占7.1%、结肠镜队列占1.5%(P=0.044)。
  • 因小息肉进展期特征归为高风险的患者比例在FIT队列为0.8%、结肠镜队列为0.4%(P=0.25)。
  • 此类高风险患者异时性进展期肿瘤发生率为17.6%,低风险患者为14.6%(RR 1.13,95%CI 0.79-1.61)。

核心结论

  • 具有进展期组织学特征的小息肉不增加异时性进展期结直肠肿瘤风险。

研究设计与样本

  • 研究收集来自美国或欧洲12个队列的结肠镜检查患者数据。
  • 粪便免疫化学检测阳性后行结肠镜检查的FIT队列共34221例。
  • 因筛查、监测或症状评估行结肠镜检查的结肠镜队列共30123例。
  • 采用逆方差随机效应模型计算比例和风险。

主要发现

  • 51510枚小息肉中,进展期组织学特征在FIT队列占7.1%、结肠镜队列占1.5%(P=0.044)。
  • 因小息肉进展期特征归为高风险的患者比例在FIT队列为0.8%、结肠镜队列为0.4%(P=0.25)。
  • 此类高风险患者异时性进展期肿瘤发生率为17.6%,低风险患者为14.6%。
  • 高风险分类的相对风险为1.13(95%CI 0.79-1.61)。

关键数值与推荐

  • 高风险定义为具有进展期组织学特征(癌、高级别上皮内瘤变、绒毛成分≥25%)的息肉。
  • 或3个及以上小(1-5 mm)或小型(6-9 mm)非进展期腺瘤。
  • 或腺瘤或无蒂锯齿状病变≥10 mm。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: With advances in endoscopic imaging, it is possible to differentiate adenomatous from hyperplastic diminutive (1-5 mm) polyps during endoscopy. With the optical Resect-and-Discard strategy, these polyps are then removed and discarded without histopathology assessment. However, failure to recognize adenomas (vs hyperplastic polyps), or discarding a polyp with advanced histologic features, could result in a patient being considered at low risk for metachronous advanced neoplasia, resulting in an inappropriately long surveillance interval. We collected data from international cohorts of patients undergoing colonoscopy to determine what proportion of patients are high risk because of diminutive polyps advanced histologic features and their risk for metachronous advanced neoplasia. METHODS: We collected data from 12 cohorts (in the United States or Europe) of patients undergoing colonoscopy after a positive result from a fecal immunochemical test (FIT cohort, n = 34,221) or undergoing colonoscopies for screening, surveillance, or evaluation of symptoms (colonoscopy cohort, n = 30,123). Patients at high risk for metachronous advanced neoplasia were defined as patients with polyps that had advanced histologic features (cancer, high-grade dysplasia, ≥25% villous features), 3 or more diminutive or small (6-9 mm) nonadvanced adenomas, or an adenoma or sessile serrated lesion ≥10 mm. Using an inverse variance random effects model, we calculated the proportion of diminutive polyps with advanced histologic features; the proportion of patients classified as high risk because their diminutive polyps had advanced histologic features; and the risk of these patients for metachronous advanced neoplasia. RESULTS: In 51,510 diminutive polyps, advanced histologic features were observed in 7.1% of polyps from the FIT cohort and 1.5% polyps from the colonoscopy cohort (P = .044); however, this difference in prevalence did not produce a significant difference in the proportions of patients assigned to high-risk status (0.8% of patients in the FIT cohort and 0.4% of patients in the colonoscopy cohort) (P = .25). The proportions of high-risk patients because of diminutive polyps with advanced histologic features who were found to have metachronous advanced neoplasia (17.6%) did not differ significantly from the proportion of low-risk patients with metachronous advanced neoplasia (14.6%) (relative risk for high-risk categorization, 1.13; 95% confidence interval 0.79-1.61). CONCLUSION: In a pooled analysis of data from 12 international cohorts of patients undergoing colonoscopy for screening, surveillance, or evaluation of symptoms, we found that diminutive polyps with advanced histologic features do not increase risk for metachronous advanced neoplasia.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Vleugels JLA, Hassan C, Senore C, et al. Diminutive Polyps With Advanced Histologic Features Do Not Increase Risk for Metachronous Advanced Colon Neoplasia. Gastroenterology. 2018. PMID: 30395813. doi:10.1053/j.gastro.2018.10.050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。